--- title: INTERCEPT Blood System Insights | Cerus (3) description: Cerus | Read interesting blog posts focused on the field of blood safety. Find the latest news on the global use of the INTERCEPT™ Blood System and discover the events where the INTERCEPT pathogen inactivation technology will be on display. (3) --- This site provides INTERCEPT product information for International audiences [Select your region](https://interceptbloodsystem.com/en) - [English](https://insights.interceptbloodsystem.com) - [Deutsch](https://insights.interceptbloodsystem.com/de) [![INTERCEPT Blood System™](https://insights.interceptbloodsystem.com/hs-fs/hubfs/Logo/logo-cerus.png?width=148&height=58&name=logo-cerus.png "INTERCEPT Blood System™")](http://interceptbloodsystem.com/) - [About](http://interceptbloodsystem.com/about) - [Insights](https://insights.interceptbloodsystem.com/) - [Cerus Campus](https://info.interceptbloodsystem.com/cerus_campus) - [Resources](http://interceptbloodsystem.com/resources) - [Contact](http://interceptbloodsystem.com/en/contact) - [Ask an expert](http://interceptbloodsystem.com/en/ask-expert) - [Blood center](https://interceptbloodsystem.com/en/blood-center) - [Healthcare professional](https://interceptbloodsystem.com/en/healthcare-professional) - [General blood safety](https://interceptbloodsystem.com/en/general-blood-safety) [![Cerus logo](https://insights.interceptbloodsystem.com/hs-fs/hubfs/Logo/logo-cerus-footer.png?width=121&height=30&name=logo-cerus-footer.png "Cerus logo")](http://interceptbloodsystem.com/) Menu # Insights [Home](https://interceptbloodsystem.com/) » [Insights](https://insights.interceptbloodsystem.com) » Insights Intercept Blood System ### Categories - [Cerus (17)](https://insights.interceptbloodsystem.com/topic/cerus) - [Economics (1)](https://insights.interceptbloodsystem.com/topic/economics) - [Guidelines (1)](https://insights.interceptbloodsystem.com/topic/guidelines) - [Hospital News (2)](https://insights.interceptbloodsystem.com/topic/hospital-news) - [Regulations (1)](https://insights.interceptbloodsystem.com/topic/regulations) - [Transfusion-Transmitted Infections (8)](https://insights.interceptbloodsystem.com/topic/transfusion-transmitted-infections) see all ## [Cerus 22/07/2019 ISBT Basel 2019 - Presentations **Presentations****Cerus Satellite Symposium at ISBT Basel 2019** "Safeguarding the blood supply against (re)emerging pathogens. Balancing blood safety and economics" Have you had the opportunity to join Cerus Satellite symposium on Tuesday June 25, 2019 at the ISBT in Basel? Regardless, we are pleased to share the presentations with you from the Cerus Symposium. ](https://insights.interceptbloodsystem.com/presentations-isbt-basel-2019) ## [Cerus 08/08/2018 Madrid adopts INTERCEPT On October 30, 2017 Cerus Corp. announced that it has entered into a two-year supply contract with Centro de Transfusion de la Comunidad de Madrid (CTCM) for the INTERCEPTTM Blood System for platelets.](https://insights.interceptbloodsystem.com/madrid-adopts-intercept) ## [Cerus 08/08/2018 EFS adopts INTERCEPT The French Ministry of Health decided late 2016 that platelet pathogen inactivation should be deployed throughout the entire French territory for the control of bacterial infections transmitted by transfusion, following the recommendations of the National Agency for the Safety of Medicines and Health Products (ANSM).](https://insights.interceptbloodsystem.com/efs-adopts-intercept) ## [Cerus 06/08/2018 Let us do something about it! In 1982 was an epidemic of HIV in San Francisco. 300 patients acquired HIV infections from blood transfusions. The patients did not blame the hospital, but simply asked “Do something about it”. This request became the personal motivation of M.D. Larry Corash to found Cerus.](https://insights.interceptbloodsystem.com/let-us-do-something-about-it) ## [Cerus 06/07/2018 2 million Swiss francs to develop a whole blood PI system in Africa The Swiss Red Cross Humanitarian Foundation has awarded a grant of 2 million Swiss Francs to Cerus, the University Hospital of Basel, and the Swiss Transfusion SRC to complete the necessary clinical studies to develop a whole blood pathogen inactivation system for use in Africa. ](https://insights.interceptbloodsystem.com/2-million-swiss-francs-to-develop-a-whole-blood-pi-system-in-africa) - [‹](https://insights.interceptbloodsystem.com/topic/cerus/page/1) - [«](https://insights.interceptbloodsystem.com/topic/cerus/page/2) - [1](https://insights.interceptbloodsystem.com/topic/cerus/page/1) - [2](https://insights.interceptbloodsystem.com/topic/cerus/page/2) - [3](https://insights.interceptbloodsystem.com/topic/cerus/page/3) - [›](https://insights.interceptbloodsystem.com/topic/cerus/page/0) - [»](https://insights.interceptbloodsystem.com/topic/cerus/page/3) ### Newsletter Want to stay updated on the latest pathogen inactivation news? You can receive our highlights by subscribing to our newsletter. [Subscribe to our newsletter](https://info.interceptbloodsystem.com/en/newsletter) ### Ask an Expert Do you have questions about the INTERCEPT™ Blood System, blood safety or blood transfusions? The INTERCEPT team has plenty of knowledge and expertise. [Ask an Expert](http://interceptbloodsystem.com/ask-expert) [![Cerus logo](https://insights.interceptbloodsystem.com/hs-fs/hubfs/Logo/logo-cerus-footer.png?width=121&height=30&name=logo-cerus-footer.png "Cerus logo")](http://interceptbloodsystem.com/) - [Legal Info](http://interceptbloodsystem.com/legal-info) - [Privacy Policy](http://interceptbloodsystem.com/privacy-policy) - [Cookies](http://interceptbloodsystem.com/cookies) The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions. Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation. © 2023 Cerus Corporation. All Rights Reserved. MKT-EN 00157 v43.0